<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04134273</url>
  </required_header>
  <id_info>
    <org_study_id>CLPG 1809</org_study_id>
    <nct_id>NCT04134273</nct_id>
  </id_info>
  <brief_title>Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris</brief_title>
  <official_title>A Randomized, Double-Blind, Multiple Center Placebo Controlled Study Comparing Taro Product to RLD and Both Treatments to a Placebo Control in the Treatment of Acne Vulgaris.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taro Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taro Pharmaceuticals USA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the therapeutic equivalence and safety of Taro Product to RLD in
      the treatment of acne vulgaris.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study objectives are to evaluate the therapeutic equivalence and safety of Taro Product
      to RLD in the treatment of acne vulgaris and to demonstrate the superiority of the efficacy
      of the test and reference products over the placebo control.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 20, 2019</start_date>
  <completion_date type="Actual">October 15, 2019</completion_date>
  <primary_completion_date type="Actual">September 17, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Demonstration of Bioequivalence</measure>
    <time_frame>Week 12</time_frame>
    <description>Demonstration of Bioequivalence in percent change in inflammatory and non-inflammatory lesion counts.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1260</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>CLPG Topical Gel 1%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clindamycin Phosphate Topical Gel 1%, applied to the face twice a day for 84 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clindamycin Phosphate Topical Gel 1%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clindamycin Phosphate Topical Gel 1%, applied to the face twice a day for 84 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle of the test product</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (vehicle of the test product), applied to the face twice a day for 84 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CLPG Topical Gel 1%</intervention_name>
    <description>Clindamycin Phosphate Topical Gel 1% (Taro Pharmaceuticals U.S.A, Inc.)</description>
    <arm_group_label>CLPG Topical Gel 1%</arm_group_label>
    <other_name>Topical Gel 1%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clindamycin</intervention_name>
    <description>Clindamycin Phosphate topical gel 1%</description>
    <arm_group_label>Clindamycin Phosphate Topical Gel 1%</arm_group_label>
    <other_name>Topical Gel 1%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (vehicle of the test product) (Taro Pharmaceuticals Inc.)</description>
    <arm_group_label>Vehicle of the test product</arm_group_label>
    <other_name>Vehicle</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or non-pregnant female aged ≥ 12 and ≤ 40 years with a clinical diagnosis
             of acne vulgaris

          -  Subjects who are 18 years of age or older (up to the age of 40) must have provided IRB
             approved written informed consent. Subjects 12 to 17 years of age, inclusive, must
             have provided IRB approved written assent; this written assent must be accompanied by
             an IRB approved written informed consent from the Subject's legally acceptable
             representative (i.e., parent or guardian).

          -  Subjects must have a definite clinical diagnosis of acne vulgaris severity grade 2, 3,
             or 4 as per the Investigator's Global Assessment (IGA).

        Exclusion Criteria:

          -  Female Subjects who are pregnant, nursing or planning to become pregnant during study
             participation.

          -  Subjects with a known hypersensitivity to clindamycin or lincomycin and/or any
             ingredients in the study drugs.

          -  Subjects with the presence of any skin condition that would interfere with the
             diagnosis or assessment of acne vulgaris (e.g., on the face: rosacea, dermatitis,
             psoriasis, squamous cell carcinoma, eczema, acneiform eruptions caused by medications,
             steroid acne, steroid folliculitis, or bacterial folliculitis).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Catawba Research, LLC</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 18, 2019</study_first_submitted>
  <study_first_submitted_qc>October 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2019</study_first_posted>
  <last_update_submitted>October 18, 2019</last_update_submitted>
  <last_update_submitted_qc>October 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Clindamycin palmitate</mesh_term>
    <mesh_term>Clindamycin phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

